Lung Cancer News and Research

Latest Lung Cancer News and Research

New class of drugs hold promise against aggressive forms of pancreatic cancer

Cancer Research UK-funded scientists have shown how a promising new class of drugs might be used to treat aggressive forms of pancreatic cancer, according to a study published in Nature.

30 Apr 2012

MCC researchers aim to improve cancer patient's quality of life and care

Researchers at Moffitt Cancer Center have placed new emphasis on gathering data on cancer patient quality of life during both treatment and survivorship. Their focus is on gathering and using that data to develop interventions to improve the quality of life for patients in treatment and for cancer survivors.

30 Apr 2012

Research roundup: Practice guidelines may not stop defensive medicine; English language ability tied to hospital readmission rates

The Value of Clinical Practice Guidelines As Malpractice "Safe Harbors" -- Overspending on health care has frequently been attributed to doctors practicing defensive medicine -- ordering extra tests, for example -- so that they avoid malpractice lawsuits. The authors of this brief write that while some have said clinical guidelines "should give caregivers a liability 'safe harbor,' shielding them from any malpractice claim for failing to provide services not included in the guideline."

27 Apr 2012

Combination of Velcade and Fasudil could treat NSCLC

A common cancer drug and a drug used for a rare condition affecting the heart could together treat an aggressive form of lung cancer called non-small cell lung cancer (NSCLC), according to a study published in Cell today.

27 Apr 2012

Aspirin can reduce chance of dying from bowel cancer by 30%

Taking aspirin after being diagnosed with bowel cancer can reduce the chance of dying from the disease by 30 per cent, new research shows today.

27 Apr 2012

Aspirin reduces bowel cancer death and lung cancer incidence: Research suggests

There is previous evidence suggesting aspirin might prevent certain cancers from developing in the first place. And more recent work suggests it might also work as a cancer therapy - slowing down or preventing a cancer's spread. But the drug can also have unpleasant and dangerous side effects, causing irritation of the stomach lining and internal bleeds in a very small minority of patients.

26 Apr 2012

CytRx commences INNO-206 Phase 2 clinical trial for pancreatic cancer

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced the initiation of a Phase 2 clinical trial evaluating the preliminary efficacy and safety of INNO-206 in patients with advanced pancreatic ductual adenocarcinomas (PDA) who have progressed after receiving two prior therapies.

26 Apr 2012

MMP-10 gene plays a dual role in lung cancer

A single gene that promotes initial development of the most common form of lung cancer and its lethal metastases has been identified by researchers at Mayo Clinic in Florida.

25 Apr 2012

Cancer, genetic screenings under scrutiny

Various news outlets covered issues around cancer screening, diagnosis and treatment.

23 Apr 2012

Study finds survival advantage for Hispanic lung cancer patients

A new analysis has found that Hispanic lung cancer patients seem to live longer than white or black patients. Published early online in Cancer, a peer-reviewed journal of the American Cancer Society, the study suggests that, as with several other types of cancer, certain yet-to-be-defined genetic and/or environmental factors put Hispanic patients at a survival advantage.

23 Apr 2012

NZ all in for plain tobacco packaging

New Zealand’s cabinet has agreed in principle to introduce plain packaging for all tobacco products in New Zealand, following a similar move in Australia.

22 Apr 2012

VeriStrat test may be useful for NSCLC clinical decision-making

Results from the combined analysis of two European Phase II trials were presented today at the 3rd European Lung Cancer Conference in Geneva, Switzerland. The VeriStrat retrospective analysis was performed on serum samples from advanced non-squamous non-small cell lung cancer (NSCLC) patients treated with the combination therapy bevacizumab plus erlotinib.

21 Apr 2012

Research roundup: Caring for dual eligibles; Antitrust policy and the health law

Using data from the Centers for Disease Control and Prevention (CDC), this report notes a systematic difference in life expectancy across region and race. "Within in each sex-race group, there are striking geographical differences in the probability of survival to age 70. ... These differences are larger for males than females within each race and larger for blacks than whites within each sex."

21 Apr 2012

Results from Boehringer Ingelheim's afatinib Phase III lung cancer trial

Highly anticipated results from LUX-Lung 3, the pivotal Phase III lung cancer trial investigating Boehringer Ingelheim's front running oncology investigational compound, the ErbB Family Blocker afatinib, in patients with EGFR mutations, will be presented at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago from 1 - 5 June 2012.

21 Apr 2012

Possibility to render cancer tumours harmless without affecting other cells

New research findings show how it may be possible to render cancer tumours harmless without affecting the other cells and tissues in the body. The findings apply to cancers including breast, lung and bowel cancer. The study was carried out at Lund University in Sweden.

20 Apr 2012

Developments in mesothelioma treatment presented at 3rd European Lung Cancer Conference

New results presented at 3rd European Lung Cancer Conference in Geneva, Switzerland show important steps being made to improve the diagnosis and treatment of malignant pleural mesothelioma, an aggressive cancer of the outer lining of the lungs caused by asbestos exposure.

19 Apr 2012

NSCLC patients with EGFR mutations benefit from erlotinib-first regimen

Patients with advanced non-small cell lung cancer should only receive treatment with the drug erlotinib before receiving standard chemotherapy if their tumor is known to harbor EGFR mutations, researchers report at the 3rd European Lung Cancer Conference in Geneva, Switzerland.

19 Apr 2012

New studies on personalized lung cancer treatment presented at 3rd ELCC

Several new studies that may help doctors tailor lung cancer treatment to the characteristics of individual patients and of their tumors are being presented at the 3rd European Lung Cancer Conference in Geneva.

19 Apr 2012

New techniques show promise in detecting early-stage lung cancer

New techniques for identifying lung cancer earlier -including a new type of chest screening, a nanotech 'nose' and a method to examine the cells of the cheek-- are showing substantial promise, according to presentations at the 3rd European Lung Cancer Conference (ELCC) in Geneva.

19 Apr 2012

New genetic signature may predict NSCLC patients at risk of relapse

A new genetic signature identified by Spanish researchers may provide doctors with robust and objective information about which patients with early stage lung cancer are at low or high risk of relapse following surgery, investigators report at the 3rd European Lung Cancer Conference in Geneva. Their work also opens new avenues for immunotherapy for lung cancer.

19 Apr 2012